Back to News
Market Impact: 0.3
SeaStar Reports Higher Survival With QUELIMMUNE In Pediatric Kidney Injury Analysis
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
SeaStar Medical said critically ill pediatric patients with sepsis-associated acute kidney injury treated with QUELIMMUNE (SCD-PED) had significantly higher survival rates than a historical comparison group. The provided article excerpt gives no survival-rate figures or further study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ICU0.65
More News
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Apple’s $2,000 iPhone Duo Debuts With Limited Supply
- Boeing 777 freighter output halted for two months over supplier row
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- Exclusive-Boeing supplier dispute has halted 777 freighter production for two months, sources say
- Volvo Cars shares plunge 25% amid China sales slump and fresh job cuts